

CASE 34056-US-PCT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1:10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

LANG, ET AL.

INTERNATIONAL APPLICATION NO: PCT/US2004/023726

FILED: 23 JULY 2004

U.S. APPLICATION NO: 10/565,452

35 USC §371 DATE: 5 MAY 2006

FOR: P-38 KINASE INHIBITORS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed January 20, 2006. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/US2004/023726, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-4125



Sophie Binet-Cross
Attorney for Applicants
Reg. No. 59,494

Date: February 27, 2009